Continuous Glucose Monitoring in Prediabetes
- Sponsor
- University of Hartford
- Study ID
- NCT07455435
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Prediabetes
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- CGM Access — BEHAVIORALThe intervention is the access to the real-time glucose via a CGM system.
Study Details
This research explores how wearable glucose monitors might help prevent type 2 diabetes in people at risk of developing the disease. Type 2 diabetes affects more than 1 in 10 Americans and costs the nation $327 billion annually. Even though it's clear that physical activity helps prevent diabetes, and that even small increases in daily movement (like walking or climbing stairs) can significantly lower risk, getting people to be more active remains challenging. A device called a continuous glucose monitor (CGM) might offer a solution. This small wearable sensor tracks blood sugar levels throughout the day and sends the information to a phone or watch. While these devices are already helping people who have diabetes manage their condition better, the investigators want to study if wearing a CGM may encourage at-risk people to become more physically active. The investigators are particularly interested in seeing whether real-time blood sugar data plus education can be an effective tool to promote lifestyle changes, such as walk more steps every day. The study also aims to examine whether using a CGM helps stabilize blood sugar levels in prediabetes. The researchers believe that even short-term use of these monitors could lead to increased physical activity and more stable blood sugar levels, potentially helping prevent diabetes development.
Key Dates
- First listed
- Mar 6, 2026
- Start date
- Mar 21, 2026
- Status verified
- Feb 2026
- Primary completion
- Dec 31, 2026
- Completion
- May 1, 2027
Study Design
- Enrollment
- 50 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- No Intervention: CGM Blind groupThe control group will wear the CGM for 20 days but without access to the real-time glucose data (blind mode). They will receive the data upon completion of the study.
- Experimental: CGM Unblind groupThe CGM unblind group will wear the CGM for 20 days. They will have the real time glucose data during the study.
Primary Outcome Measure
Physical activity level [ Time Frame: from day 1 to day 20 ]
Central Contacts
- Jinghui Yang, PT, MPT, PhD347-429-0843
Related Studies
- Blood Markers of Early Pancreas CancerRecruiting · University of Nebraska · Omaha, Nebraska
- Bromocriptine for Patients With Schizophrenia and PrediabetesPHASE4 · Not Yet Recruiting · VA Pittsburgh Healthcare System · Pittsburgh, Pennsylvania
- Glucose Variability and Cognition in PrediabetesRecruiting · University of Maryland, Baltimore · Baltimore, Maryland
- Mechanisms for Activation of Beige Adipose Tissue in HumansPHASE2 · Recruiting · Philip Kern · Lexington, Kentucky